To our knowledge, this is the first randomized clinical trial to compare the intracranial efficacy and safety of gefitinib plus chemotherapy with gefitinib as first-line treatment in EGFR-mutant NSCLC with brain metastases. Here, EGFR is linked to non-small cell lung carcinoma.